Industries > Pharma > Global Rheumatoid Arthritis Drugs Market Forecast 2019-2029

Global Rheumatoid Arthritis Drugs Market Forecast 2019-2029

Biologics, Non-Biologics, NSAIDs, sDMARDs and Others

PUBLISHED: 17 December 2018
PAGES: 232
PRODUCT CODE: PHA0345
SUBMARKET: Therapeutic Drugs

Clear
WOOCS 2.2.1
SKU: PHA0345 Categories: , Tags: , , , ,

The global rheumatoid arthritis drugs market will reach $47bn in 2024. In 2018, the Biologics submarket held 87% of the Global Rheumatoid Arthritis drugs market.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 232-page report you will receive 234 charts– all unavailable elsewhere.

The 232-page report provides clear detailed insight into the rheumatoid arthritis market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

Global Rheumatoid Arthritis Market from 2019-2029

• Forecast of the Global Rheumatoid Arthritis market by Submarket:
• Biologics
• Non-Biologics: NSAIDs, sDMARDs and Others

• Forecast of the leading drugs in the Global Rheumatoid Arthritis market:
• Humira
• Enbrel
• Remicade
• Rituxan/MabThera
• Simponi/Simponi Aria
• Orencia
• Actemra/Roactemra
• Cimzia
• Celebrex
• Xeljanz
• Arcoxia
• Others

Global Rheumatoid Arthritis Drugs Market Forecast 2019-2029

• This report provides individual revenue forecasts to 2029 for these regional and national markets:
• North America: US, Canada
• Europe: Germany, France, United Kingdom, Italy, Spain, Russia and rest of Europe
• Asia-Pacific: Japan, China, India and rest of Asia-Pacific
• Latin America: Brazil, Mexico, Rest of Latin America
• Middle East & Africa: Saudi Arabia, South Africa, Rest of MEA

Each regional market is further segmented into Biologics, Non-Biologics, NSAIDs, sDMARDs and Others

• Our study discusses the selected leading companies that are the major players in the rheumatoid arthritis market:
• AbbVie
• Amgen
• AstraZeneca
• BMS
• Eli Lilly
• Johnson & Johnson
• Merck & Co
• Novartis
• Pfizer
• Roche
• Sanofi
• UCB

• Our study discusses selected compounds under development for rheumatoid arthritis.

• This study provides a SWOT and STEP analysis of the rheumatoid arthritis drugs market.

Visiongain’s study is intended for anyone requiring commercial analyses for the rheumatoid arthritis market. You find data, trends and predictions.

Buy our report today Global Rheumatoid Arthritis Drugs Market Forecast 2019-2029: Biologics, Non-Biologics, NSAIDs, sDMARDs and Others

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Global Rheumatoid Arthritis Drugs Market Forecast 2019-2029


Download sample pages

Complete the form below to download your free sample pages for Global Rheumatoid Arthritis Drugs Market Forecast 2019-2029


Latest Pharma news

Visiongain Publishes Pharmaceutical Product Information Management System Market Report 2020-2030

Some of the major factors fuelling the growth of global market include significant advantages associated with PIM solutions and inclination towards centralized models among across pharma sector.

19 October 2020

READ

Visiongain Publishes Pulmonary/Respiratory Drug Delivery Market Report 2020-2030

The coronavirus outbreak has negatively impacted all the economies and industries across the globe. Hence, for the next 1-2 years, the global respiratory drug delivery market is expected to take a hit.

12 October 2020

READ

Visiongain Publishes Real-World Evidence (RWE) Solutions Market Report 2020-2030

We predict strong revenue growth through to 2030. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

02 October 2020

READ

Visiongain Publishes mRNA Vaccines Market Report 2021-2031

The development of mRNA vaccines is driven by new biotechnologies and nanotechnologies. Emerging delivery technologies, such as electroporation (EP), innovative vaccine formats like mRNA preventive boost, and new molecular adjuvant technologies are particularly important for mRNA vaccines reaching their potential.

02 October 2020

READ

Categories

Category